ICON Public Company (ICLR) investor relations material

Demand environment and industry trends

• RFP flows have increased mid-single digits overall, with stronger growth in biotech, indicating a period of inflection for demand in the sector.

• Large pharma is deploying balance sheets more actively, deal flow is rising, and pipeline reprioritization is normalizing.

• Biotechs are deploying raised capital more assertively, and mid-sized companies are showing increased licensing and trial activity.

• The environment is shifting back to innovative, hybrid sourcing models, reminiscent of 2015–2019, with a focus on optimizing interfaces between in-house, insourced, and outsourced work.

• The definition of a clinical CRO is broadening, with expansion into lab, early development, and real-world evidence, reflecting a trend toward diversified life sciences companies.

Pricing dynamics and partnership models

• Pricing pressure in the CRO sector has been driven by similar pressures in pharma, but recent political and market stabilization is seen as positive.

• Renewals and rebidding of preferred provider partnerships in large pharma have been extensive, with new five-year terms impacting future awards.

• The sector is moving from rate-based to value-based economics, focusing on efficiency and cost reduction in development programs.

• FSP (functional service provider) models are evolving, with successful partnerships requiring clear delegation and a focus on value, not just capacity management.

• Milestone-based contracts are now more common than unit-based, aligning incentives for efficiency and timely delivery.

Operational efficiency and technology

• Efficiency gains are being achieved through process optimization, role stratification, and automation, with examples of reducing clinical oversight costs by at least 20%.

• Investment of $300 million over three years is planned for digital innovation, especially AI, to drive further disruption and efficiency.

• Partnerships are increasingly co-invested, with risk and upside shared, especially in biotech, where agility and speed are highly valued.

• The ability to measure and improve cost per output is a key differentiator, with external partners often better positioned to drive these improvements.

• Headcount has been reduced by about 5% year-over-year, reflecting both demand response and efficiency gains from technology.